Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Development process of a mobile electronic medical record for nurses: a single case study.

Vossebeld DM, Puik ECN, Jaspers JEN, Schuurmans MJ.

BMC Med Inform Decis Mak. 2019 Jan 14;19(1):11. doi: 10.1186/s12911-018-0726-3.

2.

Implementing Medical Technological Equipment in the OR: Factors for Successful Implementations.

Sewberath Misser N, van Zaane B, Jaspers JEN, Gooszen H, Versendaal J.

J Healthc Eng. 2018 Aug 29;2018:8502187. doi: 10.1155/2018/8502187. eCollection 2018. Review.

3.

Technical feasibility of personalized articulating knee joint distraction for treatment of tibiofemoral osteoarthritis.

Struik T, Jaspers JEN, Besselink NJ, van Roermund PM, Plomp S, Rudert MJ, Lafeber FPJG, Mastbergen SC.

Clin Biomech (Bristol, Avon). 2017 Nov;49:40-47. doi: 10.1016/j.clinbiomech.2017.08.002. Epub 2017 Aug 12.

PMID:
28865300
4.

Development of CAR T cells designed to improve antitumor efficacy and safety.

Jaspers JE, Brentjens RJ.

Pharmacol Ther. 2017 Oct;178:83-91. doi: 10.1016/j.pharmthera.2017.03.012. Epub 2017 Mar 22. Review.

5.

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.

Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.

Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.

6.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

7.

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8409-14. doi: 10.1073/pnas.1500223112. Epub 2015 Jun 22.

8.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

9.

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.

Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.

10.

Monitoring of tumor response to Cisplatin using optical spectroscopy.

Spliethoff JW, Evers DJ, Jaspers JE, Hendriks BH, Rottenberg S, Ruers TJ.

Transl Oncol. 2014 Apr;7(2):230-9. doi: 10.1016/j.tranon.2014.02.009. Epub 2014 Mar 4.

11.

Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus.

Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC.

PLoS One. 2013;8(3):e60357. doi: 10.1371/journal.pone.0060357. Epub 2013 Mar 28.

12.

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.

Warmoes M, Jaspers JE, Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez CR.

Mol Cell Proteomics. 2013 May;12(5):1319-34. doi: 10.1074/mcp.M112.024182. Epub 2013 Feb 8.

13.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

14.

The use of near-infrared light for safe and effective visualization of subsurface blood vessels to facilitate blood withdrawal in children.

Cuper NJ, Klaessens JH, Jaspers JE, de Roode R, Noordmans HJ, de Graaff JC, Verdaasdonk RM.

Med Eng Phys. 2013 Apr;35(4):433-40. doi: 10.1016/j.medengphy.2012.06.007. Epub 2012 Jul 27.

PMID:
22841651
15.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.

Cancer Res. 2012 May 1;72(9):2350-61. doi: 10.1158/0008-5472.CAN-11-4201. Epub 2012 Mar 6.

16.

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.

Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.

Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.

17.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T.

Cancer Res. 2010 Aug 1;70(15):6268-76. doi: 10.1158/0008-5472.CAN-09-3416. Epub 2010 Jul 14. Erratum in: Cancer Res. 2010 Oct 1;70(19):7734. Djurenovic, Tatjana [corrected to Djureinovic, Tatjana].

18.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

Zander SA, Kersbergen A, van der Burg E, de Water N, van Tellingen O, Gunnarsdottir S, Jaspers JE, Pajic M, Nygren AO, Jonkers J, Borst P, Rottenberg S.

Cancer Res. 2010 Feb 15;70(4):1700-10. doi: 10.1158/0008-5472.CAN-09-3367. Epub 2010 Feb 9.

19.

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

Jaspers JE, Rottenberg S, Jonkers J.

Biochim Biophys Acta. 2009 Dec;1796(2):266-80. doi: 10.1016/j.bbcan.2009.07.001. Epub 2009 Jul 17. Review.

PMID:
19616605
20.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

21.

The mechanical master-slave manipulator: an instrument improving the performance in standardized tasks for endoscopic surgery.

Diks J, Jaspers JE, Wisselink W, de Mol BA, Grimbergen CA.

Surg Endosc. 2007 Jun;21(6):1025-31. Epub 2007 Feb 6.

PMID:
17279305
22.

Development of a modeling and osteotomy jig system for reconstruction of the mandible with a free vascularized fibula flap.

Strackee SD, Kroon FH, Spierings PT, Jaspers JE.

Plast Reconstr Surg. 2004 Dec;114(7):1851-8. No abstract available.

PMID:
15577358
23.

Camera and instrument holders and their clinical value in minimally invasive surgery.

Jaspers JE, Breedveld P, Herder JL, Grimbergen CA.

Surg Laparosc Endosc Percutan Tech. 2004 Jun;14(3):145-52. Review.

PMID:
15471021
24.

A realistic 3-D gated cardiac phantom for quality control of gated myocardial perfusion SPET: the Amsterdam gated (AGATE) cardiac phantom.

Visser JJ, Sokole EB, Verberne HJ, Habraken JB, van de Stadt HJ, Jaspers JE, Shehata M, Heeman PM, van Eck-Smit BL.

Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):222-8. Erratum in: Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1215-6.

PMID:
15129704
25.

An instrumented, dynamic test for anterior laxity of the ankle joint complex.

Kerkhoffs GM, Blankevoort L, Schreurs AW, Jaspers JE, van Dijk CN.

J Biomech. 2002 Dec;35(12):1665-70.

PMID:
12445620
26.

Time-action analysis of instrument positioners in laparoscopic cholecystectomy.

den Boer KT, Bruijn M, Jaspers JE, Stassen LP, Erp WF, Jansen A, Go PM, Dankelman J, Gouma DJ.

Surg Endosc. 2002 Jan;16(1):142-7. Epub 2001 Oct 19.

PMID:
11961625
27.

Modeling a fibula transplant in mandibular reconstructions: evaluation of the effects of a minimal number of osteotomies on the contour of the jaw.

Strackee SD, Kroon FH, Jaspers JE, Bos KE.

Plast Reconstr Surg. 2001 Dec;108(7):1915-21; discussion 1922-3.

PMID:
11743376
28.

Design and feasibility of PASSIST, a passive instrument positioner.

Jaspers JE, Den Boer KT, Sjoerdsma W, Bruijn M, Grimbergen CA.

J Laparoendosc Adv Surg Tech A. 2000 Dec;10(6):331-5.

PMID:
11132913

Supplemental Content

Loading ...
Support Center